Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Amarendra Pegu, Sarah O’Connell, Stephen D. Schmidt, et al.
Science (2021) Vol. 373, Iss. 6561, pp. 1372-1377
Open Access | Times Cited: 541

Showing 1-25 of 541 citing articles:

The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 11, pp. 817-838
Open Access | Times Cited: 939
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 14, pp. 1279-1291
Open Access | Times Cited: 571
Homologous and Heterologous Covid-19 Booster Vaccinations
Robert L. Atmar, Kirsten E. Lyke, Meagan E. Deming, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 11, pp. 1046-1057
Open Access | Times Cited: 532
Humoral and cellular immune memory to four COVID-19 vaccines
Zeli Zhang, José Mateus, Camila H. Coelho, et al.
Cell (2022) Vol. 185, Iss. 14, pp. 2434-2451.e17
Open Access | Times Cited: 444
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
Eddy Pérez-Then, Carolina Lucas, Valter Silva Monteiro, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 481-485
Open Access | Times Cited: 379
Covid-19 Vaccines — Immunity, Variants, Boosters
Dan H. Barouch
New England Journal of Medicine (2022) Vol. 387, Iss. 11, pp. 1011-1020
Open Access | Times Cited: 378
Human genetic and immunological determinants of critical COVID-19 pneumonia
Qian Zhang, Paul Bastard, Adem Karbuz, et al.
Nature (2022) Vol. 603, Iss. 7902, pp. 587-598
Open Access | Times Cited: 315
SARS-CoV-2 viral load and shedding kinetics
Olha Puhach, Benjamin Meyer, Isabella Eckerle
Nature Reviews Microbiology (2022)
Open Access | Times Cited: 302
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
José Mateus, Jennifer M. Dan, Zeli Zhang, et al.
Science (2021) Vol. 374, Iss. 6566
Open Access | Times Cited: 290
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
Rolando Pajón, Nicole A. Doria‐Rose, Xiaoying Shen, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 11, pp. 1088-1091
Open Access | Times Cited: 239
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
Karin Bok, Sandra Sitar, Barney S. Graham, et al.
Immunity (2021) Vol. 54, Iss. 8, pp. 1636-1651
Open Access | Times Cited: 230
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
Katia Bruxvoort, Lina S. Sy, Lei Qian, et al.
BMJ (2021), pp. e068848-e068848
Open Access | Times Cited: 221
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Alessandro Sette, Shane Crotty
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 27-46
Open Access | Times Cited: 214
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
Venkata-Viswanadh Edara, Kelly E. Manning, Madison Ellis, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 2, pp. 100529-100529
Open Access | Times Cited: 209
A Global Map of COVID-19 Vaccine Acceptance Rates per Country: An Updated Concise Narrative Review
Malik Sallam, Mariam Alsanafi, Mohammed Sallam
Journal of Multidisciplinary Healthcare (2022) Vol. Volume 15, pp. 21-45
Open Access | Times Cited: 204
Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis
Ioannis P. Trougakos, Evangelos Terpos, Harry Alexopoulos, et al.
Trends in Molecular Medicine (2022) Vol. 28, Iss. 7, pp. 542-554
Open Access | Times Cited: 196
Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection
Ariel Israel, Yotam Shenhar, Ilan Green, et al.
Vaccines (2021) Vol. 10, Iss. 1, pp. 64-64
Open Access | Times Cited: 189
mRNA Vaccines in the COVID-19 Pandemic and Beyond
Michael J. Hogan, Norbert Pardi
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 17-39
Open Access | Times Cited: 177
Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines
Ai‐ris Y. Collier, Jingyou Yu, Katherine McMahan, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 21, pp. 2010-2012
Open Access | Times Cited: 177
T cell immunity to COVID-19 vaccines
E. John Wherry, Dan H. Barouch
Science (2022) Vol. 377, Iss. 6608, pp. 821-822
Open Access | Times Cited: 175
Defining the risk of SARS-CoV-2 variants on immune protection
Marciela M. DeGrace, Elodie Ghedin, Matthew B. Frieman, et al.
Nature (2022) Vol. 605, Iss. 7911, pp. 640-652
Open Access | Times Cited: 152
Immunity to SARS‐CoV‐2 induced by infection or vaccination
Xaquín Castro Dopico, Sebastian Ols, Karin Loré, et al.
Journal of Internal Medicine (2021) Vol. 291, Iss. 1, pp. 32-50
Open Access | Times Cited: 145
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
Spyros Chalkias, Frank Eder, Brandon Essink, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2388-2397
Open Access | Times Cited: 126
Page 1 - Next Page

Scroll to top